• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Voss Capital, Lp claimed ownership of 1,016,208 shares (SEC Form 3)

    10/3/25 3:09:44 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNTX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Voss Capital, LP

    (Last) (First) (Middle)
    3773 RICHMOND AVENUE, SUITE 850

    (Street)
    HOUSTON TX 77046

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    09/24/2025
    3. Issuer Name and Ticker or Trading Symbol
    Rein Therapeutics, Inc. [ RNTX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock, $0.001 par value(1) 699,440 I By: Voss Value Master Fund, LP(2)
    Common Stock, $0.001 par value(1) 316,768 I By: Voss Value-Oriented Special Situations Fund, LP(3)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Voss Capital, LP

    (Last) (First) (Middle)
    3773 RICHMOND AVENUE, SUITE 850

    (Street)
    HOUSTON TX 77046

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Voss Value Master Fund, LP

    (Last) (First) (Middle)
    3773 RICHMOND AVENUE, SUITE 850

    (Street)
    HOUSTON TX 77046

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Voss Value-Oriented Special Situations Fund, LP

    (Last) (First) (Middle)
    3773 RICHMOND AVENUE, SUITE 850

    (Street)
    HOUSTON TX 77046

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Voss Advisors GP, LLC

    (Last) (First) (Middle)
    3773 RICHMOND AVENUE, SUITE 850

    (Street)
    HOUSTON TX 77046

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Cocke Travis W.

    (Last) (First) (Middle)
    3773 RICHMOND AVENUE, SUITE 850

    (Street)
    HOUSTON TX 77046

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. This Form 3 is filed jointly by Voss Value Master Fund, LP ("Voss Value Master Fund"), Voss Value-Oriented Special Situations Fund, LP ("Voss Value-Oriented Special Situations Fund"), Voss Advisors GP, LLC ("Voss GP"), Voss Capital, LP ("Voss Capital") and Travis W. Cocke (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
    2. Securities owned directly by Voss Value Master Fund. Voss GP, as the general partner of Voss Value Master Fund, may be deemed to beneficially own the securities owned directly by Voss Value Master Fund. Voss Capital, as the investment manager of Voss Value Master Fund, may be deemed to beneficially own the securities owned directly by Voss Value Master Fund. Mr. Cocke, as the managing member of Voss Capital and Voss GP, may be deemed to beneficially own the securities owned directly by Voss Value Master Fund.
    3. Securities owned directly by Voss Value-Oriented Special Situations Fund. Voss GP, as the general partner of Voss Value-Oriented Special Situations Fund, may be deemed to beneficially own the securities owned directly by Voss Value-Oriented Special Situations Fund. Voss Capital, as the investment manager of Voss Value-Oriented Special Situations Fund, may be deemed to beneficially own the securities owned directly by Voss Value-Oriented Special Situations Fund. Mr. Cocke, as the managing member of Voss Capital and Voss GP, may be deemed to beneficially own the securities owned directly by Voss Value-Oriented Special Situations Fund.
    Voss Capital, LP; By: /s/ Travis W. Cocke, Managing Member 10/03/2025
    Voss Value Master Fund, LP; By: Voss Advisors GP, LLC; By: /s/ Travis W. Cocke, Managing Member 10/03/2025
    Voss Value-Oriented Special Situations Fund, LP; By: Voss Advisors GP, LLC; By: /s/ Travis W. Cocke, Managing Member 10/03/2025
    Voss Advisors GP, LLC; By: /s/ Travis W. Cocke, Managing Member 10/03/2025
    /s/ Travis W. Cocke 10/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RNTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNTX

    DatePrice TargetRatingAnalyst
    9/22/2025$10.00Buy
    H.C. Wainwright
    1/28/2025$8.00Buy
    Rodman & Renshaw
    More analyst ratings

    $RNTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Voss Capital, Lp bought $423,466 worth of shares (306,050 units at $1.38) (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    10/28/25 6:45:45 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF

    AUSTIN, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that a new preprint has been posted to medRxiv describing clinical and translational findings from an inhaled, dose-escalation study of Rein's lead drug candidate, LTI-03, in idiopathic pulmonary fibrosis (IPF). The preprint, titled "Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study," was authored by an international team of investigators, including Philip L. Molyneaux, MD, Nikhil A. Hi

    11/6/25 7:30:00 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

    FDA lifts clinical hold following review of Company's Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites.Early data suggests that LTI-03 may not only slow fibrosis but also promote lung healing. AUSTIN, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the U.S. Food and Drug Administration (FDA) has lifted the full clinical hold on the Company's Phase 2 "RENEW" trial evaluating LTI-03 in patient

    11/3/25 7:30:00 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

    EMA approval covers study sites in Germany and Poland as part of the Company's global Phase 2 RENEW trialTrial will evaluate LTI-03, a first-in-class therapy designed to both reduce lung scarring and promote repair AUSTIN, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has received authorization from the European Medicines Agency (EMA) to initiate the Company's Phase 2 "RENEW" clinical trial of its lead candidate, LTI-03, for the treatment of idiopathic pulmona

    10/9/25 7:30:00 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Rein Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $10.00

    9/22/25 8:32:15 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Rein Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00

    1/28/25 7:16:42 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    SEC Filings

    View All

    Rein Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

    11/3/25 7:45:11 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rein Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

    10/24/25 5:08:06 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Rein Therapeutics Inc.

    8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

    10/9/25 7:45:46 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Voss Capital, Lp bought $423,466 worth of shares (306,050 units at $1.38) (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    10/28/25 6:45:45 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Voss Capital, Lp claimed ownership of 1,016,208 shares (SEC Form 3)

    3 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    10/3/25 3:09:44 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Aivado Manuel

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    7/23/25 7:42:24 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care